Modality
Radioligand
MOA
BCMA ADC
Target
FGFR
Pathway
Notch
Asthma
Development Pipeline
Preclinical
~Nov 2009
→ ~Feb 2011
Phase 1
~May 2011
→ ~Aug 2012
Phase 2
~Nov 2012
→ ~Feb 2014
Phase 3
~May 2014
→ ~Aug 2015
NDA/BLA
~Nov 2015
→ ~Feb 2017
Approved
May 2017
→ May 2031
ApprovedCurrent
NCT04085450
1,943 pts·Asthma
2020-08→2031-05·Recruiting
NCT07650272
2,979 pts·Asthma
2025-06→TBD·Not yet recruiting
NCT04844680
1,079 pts·Asthma
2017-05→2030-07·Completed
6,001 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2030-07-224.3y awayPh3 Readout· Asthma
2031-05-035.1y awayPh3 Readout· Asthma
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Approved
Complet…
Approved
Recruit…
Approved
Not yet…
Catalysts
Ph3 Readout
2030-07-22 · 4.3y away
Asthma
Ph3 Readout
2031-05-03 · 5.1y away
Asthma
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04085450 | Approved | Asthma | Recruiting | 1943 | 6MWD |
| NCT07650272 | Approved | Asthma | Not yet recr... | 2979 | UPCR |
| NCT04844680 | Approved | Asthma | Completed | 1079 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Terazumab | Recursion | Phase 3 | AHR | |
| ABS-5770 | Absci | Preclinical | FGFR |